Erythropoietin as an immunomodulating agent

Nephro-Urology Monthly

Volumn 3, Issue 4, 2011, Pages 208-212

  Lisowska, Katarzyna A ^a   Jasiulewicz, Aleksandra ^a   Bryl, Ewa ^a   Witkowski, Jacek M ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Erythropoietin; Immunomodulation; Lymphocytes; Monocytes; Protein; Receptor; STAT5

Indexed keywords

DARBEPOEITIN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CYTOKINE PRODUCTION; DRUG MECHANISM; HEMODIALYSIS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOLOGY; LEUKOCYTE; PROTEIN FUNCTION; T LYMPHOCYTE ACTIVATION;

EID: 80052975853     PISSN: 22517006     EISSN: 22517014     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Fisher JW. Erythropoietin: physiologic and pharmacologic aspects. Proc Soc Exp Biol Med. 1997;216(3):358-69
2. Ihle JN. Cytokine receptor signalling. Nature. 1995;377(6550):591-4
3. Watowich SS, Hilton DJ, Lodish HF. Activation and inhibition of erythropoietin receptor function: role of receptor dimerization. Mol Cell Biol. 1994;14(6):3535-49
4. Silva M, Benito A, Sanz C, Prosper F, Ekhterae D, Nunez G, et al. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem. 1999;274(32):22165-9
5. Gilmour KC, Pine R, Reich NC. Interleukin 2 activates STAT5 transcription factor (mammary gland factor) and specific gene expression in T lymphocytes. Proc Natl Acad Sci U S A. 1995;92(23):10772-6
6. Gobert S, Duprez V, Lacombe C, Gisselbrecht S, Mayeux P. The signal transduction pathway of erythropoietin involves three forms of mitogen-activated protein (MAP) kinase in UT7 erythroleukemia cells. Eur J Biochem. 1995;234(1):75-83
7. Halupa A, Chohan M, Stickle NH, Beattie BK, Miller BA, Barber DL. Erythropoietin receptor Y479 couples to ERK1/2 activation via recruitment of phospholipase Cgamma. Exp Cell Res. 2005;309(1):1-11
8. Mayeux P, Dusanter-Fourt I, Muller O, Mauduit P, Sabbah M, Druker B, et al. Erythropoietin induces the association of phosphatidylinositol 3'-kinase with a tyrosine-phosphorylated protein complex containing the erythropoietin receptor. Eur J Biochem. 1993;216(3):821-8
9. Chin K, Yu X, Beleslin-Cokic B, Liu C, Shen K, Mohrenweiser HW, et al. Production and processing of erythropoietin receptor transcripts in brain. Brain Res Mol Brain Res. 2000;81(1-2):29-42
10. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A. 1994;91(9):3974-8
11. Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist. 2004;9 Suppl 5:18-30
12. Sela S, Shurtz-Swirski R, Sharon R, Manaster J, Chezar J, Shkolnik G, et al. The polymorphonuclear leukocyte--a new target for erythropoietin. Nephron. 2001;88(3):205-10
13. Lisowska KA, Debska-Slizien A, Bryl E, Rutkowski B, Witkowski JM. Erythropoietin receptor is expressed on human peripheral blood T and B lymphocytes and monocytes and is modulated by recombinant human erythropoietin treatment. Artif Organs. 2010;34(8):654-62
14. Shinjo K, Takeshita A, Higuchi M, Ohnishi K, Ohno R. Erythropoietin receptor expression on human bone marrow erythroid precursor cells by a newly-devised quantitative flowcytometric assay. Br J Haematol. 1997;96(3):551-8
15. Johnson CA, Levey AS, Coresh J, Levin A, Lau J, Eknoyan G. Clinical practice guidelines for chronic kidney disease in adults: Part I. Definition, disease stages, evaluation, treatment, and risk factors. Am Fam Physician. 2004;70(5):869-76
16. Erslev AJ, Besarab A. Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney Int. 1997;51(3):622-30
17. Macdougall IC, Roberts DE, Coles GA, Williams JD. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet. 1991;20(2):99-113
18. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol. 2003;31(4):290-9
19. Herbelin A, Nguyen AT, Zingraff J, Urena P, Descamps-Latscha B. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha. Kidney Int. 1990;37(1):116-25
20. Cavaillon JM, Poignet JL, Fitting C, Delons S. Serum interleukin-6 in long-term hemodialyzed patients. Nephron. 1992;60(3):307-13
21. Herbelin A, Urena P, Nguyen AT, Zingraff J, Descamps-Latscha B. Influence of first and long-term dialysis on uraemia-associated increased basal production of interleukin-1 and tumour necrosis factor alpha by circulating monocytes. Nephrol Dial Transplant. 1991;6(5):349-57
22. Kurz P, Kohler H, Meuer S, Hutteroth T, Meyer zum Buschenfelde KH. Impaired cellular immune responses in chronic renal failure: evidence for a T cell defect. Kidney Int. 1986;29(6):1209-14
23. Lisowska KA, Debska-Slizien A, Radzka M, Witkowski JM, Rutkowski B, Bryl E. Recombinant human erythropoietin treatment of chronic renal failure patients normalizes altered phenotype and proliferation of CD4-positive T lymphocytes. Artif Organs. 2010;34(3):E77-84
24. Ueki Y, Nagata M, Miyake S, Tominaga Y. Lymphocyte subsets in hemodialysis patients treated with recombinant human erythropoietin. J Clin Immunol. 1993;13(4):279-87
25. Allegra V, Vasile A, Maschio M, Mengozzi G. Immune response after vaccination with recombinant hepatitis surface antigen in maintenance hemodialysis patients and healthy controls. Nephron. 1992;61(3):339-40
26. Tetta C, Camussi G, Turello E, Salomone M, Aimo G, Priolo G, et al. Production of cytokines in hemodialysis. Blood Purif. 1990;8(6):337-46
27. Bryl E, Vallejo AN, Weyand CM, Goronzy JJ. Down-regulation of CD28 expression by TNF-alpha. J Immunol. 2001;167(6):3231-8
28. Trzonkowski P, Mysliwska J, Debska-Slizien A, Bryl E, Rachon D, Mysliwski A, et al. Long-term therapy with recombinant human erythropoietin decreases percentage of CD152(+) lymphocytes in primary glomerulonephritis haemodialysis patients. Nephrol Dial Transplant. 2002;17(6):1070-80
29. Walunas TL, Bluestone JA. CTLA-4 regulates tolerance induction and T cell differentiation in vivo. J Immunol. 1998;160(8):3855-60
30. Tamadon MR, Khatibinezhad A, Ghorbani R, Soleimani A, Malek F, Jalalzadeh M, et al. The impact of human recombinant erythropoietinon renal function in patients with chronic kidney disease. Nephro-Urol Mon. 2011;3(2):114-7
31. Bryl E, Mysliwska J, Debska-Slizien A, Trzonkowski P, Rachon D, Bullo B, et al. Recombinant human erythropoietin stimulates production of interleukin 2 by whole blood cell cultures of hemodialysis patients. Artif Organs. 1999;23(9):809-16
32. Bryl E, Mysliwska J, Debska-Slizien A, Rachon D, Bullo B, Lizakowski S, et al. The influence of recombinant human erythropoietin on tumor necrosis factor alpha and interleukin-10 production by whole blood cell cultures in hemodialysis patients. Artif Organs. 1998;22(3):177-81
33. William J, Saad N, Salib M, Riad H, Mahran KS, Iskander I, et al. The acute effect of intravenously administered recombinant human erythropoietin on the immune response of uremic patients maintained on regular hemodialysis. Artif Organs. 1998;22(3):192-6
34. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991;174(5):1209-20
35. Itoh K, Hirohata S. The role of IL-10 in human B cell activation, proliferation, and differentiation. J Immunol. 1995;154(9):4341-50
36. Kimata H, Yoshida A, Ishioka C, Masuda S, Sasaki R, Mikawa H. Human recombinant erythropoietin directly stimulates B cell immunoglobulin production and proliferation in serum-free medium. Clin Exp Immunol. 1991;85(1):151-6
37. Witkowski JM, Bryl E. Paradoxical age-related cell cycle quickening of human CD4(+) lymphocytes: a role for cyclin D1 and calpain. Exp Gerontol. 2004;39(4):577-85
38. Pallard C, Gouilleux F, Charon M, Groner B, Gisselbrecht S, Dusanter-Fourt I. Interleukin-3, erythropoietin, and prolactin activate a STAT5-like factor in lymphoid cells. J Biol Chem. 1995;270(27):15942-5
39. Lisowska KA, Debska-Slizien A, Jasiulewicz A, Jozwik A, Rutkowski B, Bryl E, et al. Flow cytometric analysis of STAT5 phosphorylation and CD95 expression in CD4(+) T lymphocytes treated with recombinant human erythropoietin. J Recept Signal Transduct Res. 2011;31(3):241-6
40. De Maria R, Testa U, Luchetti L, Zeuner A, Stassi G, Pelosi E, et al. Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. Blood. 1999;93(3):796-803
41. Cheng J, Liu C, Koopman WJ, Mountz JD. Characterization of human Fas gene. Exon/intron organization and promoter region. J Immunol. 1995;154(3):1239-45
42. Sae-Ung N, Matsushima T, Choi I, Abe Y, Winichagoon P, Fucharoen S, et al. Role of NF-kappa B in regulation of apoptosis of erythroid progenitor cells. Eur J Haematol. 2005;74(4):315-23
43. Alderson MR, Armitage RJ, Maraskovsky E, Tough TW, Roux E, Schooley K, et al. Fas transduces activation signals in normal human T lymphocytes. J Exp Med. 1993;178(6):2231-5
44. Lifshitz L, Tabak G, Gassmann M, Mittelman M, Neumann D. Macrophages as novel target cells for erythropoietin. Haematologica. 2010;95(11):1823-31.